Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Aschan

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Bone Marrow Transplantation|February 1, 1991
Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapyJ Aschan, O Ringdén, B Sundberg, et al.
Presse Medicale (Paris, France : 1983)|April 24, 2004
Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase? A pilot trialB-M Svahn, B Bjurman, K-E Myrbäck, et al.
Transplantation|October 27, 1994
Long-term follow-up of a randomized trial comparing T cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipientsO Ringdén, M Remberger, J Aschan, et al.
Bone Marrow Transplantation|July 1, 1994
Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipientsJ Aschan, O Ringdén, E Andström, et al.
Bone Marrow Transplantation|April 1, 2003
The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantationC Nilsson, J Aschan, P Hentschke, et al.
Bone Marrow Transplantation|September 27, 2006
Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantationG Avetisyan, K Larsson, J Aschan, et al.
Bone Marrow Transplantation|December 7, 2000
Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trialB M Svahn, B Bjurman, K E Myrbäck, et al.
Clinical Transplantation|January 5, 2000
Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-upJ Aschan, S Carlens, H Hägglund, et al.
Transplantation|December 15, 1995
Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?S Klaesson, O Ringdén, P Ljungman, et al.
European Journal of Haematology|May 1, 1993
Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host diseaseJ Aschan, O Ringdén, B Sundberg, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Bone Marrow Transplantation|February 1, 1991
Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapyJ Aschan, O Ringdén, B Sundberg, et al.
Presse Medicale (Paris, France : 1983)|April 24, 2004
Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase? A pilot trialB-M Svahn, B Bjurman, K-E Myrbäck, et al.
Transplantation|October 27, 1994
Long-term follow-up of a randomized trial comparing T cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipientsO Ringdén, M Remberger, J Aschan, et al.
Bone Marrow Transplantation|July 1, 1994
Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipientsJ Aschan, O Ringdén, E Andström, et al.
Bone Marrow Transplantation|April 1, 2003
The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantationC Nilsson, J Aschan, P Hentschke, et al.
Bone Marrow Transplantation|September 27, 2006
Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantationG Avetisyan, K Larsson, J Aschan, et al.
Bone Marrow Transplantation|December 7, 2000
Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trialB M Svahn, B Bjurman, K E Myrbäck, et al.
Clinical Transplantation|January 5, 2000
Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-upJ Aschan, S Carlens, H Hägglund, et al.
Transplantation|December 15, 1995
Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?S Klaesson, O Ringdén, P Ljungman, et al.
European Journal of Haematology|May 1, 1993
Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host diseaseJ Aschan, O Ringdén, B Sundberg, et al.
Pageof 7